EMJ Oncology 8 [Supplement 4] . 2020

In this issue

The annual masterclass, organised by the Saudi Oncology Society (SOS), addressed the knowledge gaps in breast cancer care in Saudi Arabia via a virtual multidisciplinary educational exchange platform. Presentations focussed on the detection, diagnosis, and management of breast cancer, as well as clinical trial analysis. Prof Meteb Al-Foheidi discussed the subgroup analysis of the Phase III MONARCH 2 trial specifically, in which the efficacy of abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-negative advanced breast cancer was assessed.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given